Lv1
50 积分 2023-08-23 加入
Unlocking the potential of T cell engagers in solid tumors
7天前
已完结
Prognostic utility of baseline ASCL1/INSM1 expression and neutrophil-lymphocyte ratio in unresectable SCLC treated with first-line chemoimmunotherapy with or without radiotherapy
27天前
已完结
Lurbinectedin as second-line treatment for patients with small-cell lung cancer: a single-arm, open-label, phase 2 basket trial
30天前
已完结
First-Line Sunvozertinib in NSCLC with EGFR Exon 20 Insertion Mutations
1个月前
已完结
Treatment of NSCLC after chemoimmunotherapy — are we making headway?
2个月前
已完结
Single-cell screens identify ADAM12 as a fibroblast checkpoint impeding anti-tumor immunity
7个月前
已完结
Efficacy and Safety of Immunotherapy Combined with Anlotinib as First-Line Treatment in Older NSCLC Patients with PD-L1 Expression<50%
7个月前
已完结
Minimally invasive hilum-mediastinal lymph nodes dissection for non-small cell lung cancer surgery: What is the future direction?
8个月前
已完结
Determinants of successful minimally invasive surgery for resectable non–small cell lung cancer after neoadjuvant therapy
8个月前
已完结
Surgical outcomes from the phase 3 CheckMate 816 trial: Nivolumab (NIVO) + platinum-doublet chemotherapy (chemo) vs chemo alone as neoadjuvant treatment for patients with resectable non-small cell lung cancer (NSCLC)
8个月前
已完结
皖公网安备34019202002308
